share_log

EyePoint Pharmaceuticals | DEFA14A: Others

EyePoint Pharmaceuticals | DEFA14A: Others

EyePoint Pharmaceuticals | DEFA14A:其他
美股SEC公告 ·  04/26 16:06
Moomoo AI 已提取核心訊息
EyePoint Pharmaceuticals, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) on April 26, 2024. The materials are related to a proxy statement under Schedule 14A of the Securities Exchange Act of 1934. This filing, indicated by the form DEFA14A, is an amendment that includes further materials but does not require an additional filing fee. The document was filed by EyePoint Pharmaceuticals as the registrant and does not involve any third party filers. The nature of the additional materials was not specified in the announcement.
EyePoint Pharmaceuticals, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) on April 26, 2024. The materials are related to a proxy statement under Schedule 14A of the Securities Exchange Act of 1934. This filing, indicated by the form DEFA14A, is an amendment that includes further materials but does not require an additional filing fee. The document was filed by EyePoint Pharmaceuticals as the registrant and does not involve any third party filers. The nature of the additional materials was not specified in the announcement.
EyePoint Pharmicals, Inc.已於2024年4月26日向美國證券交易委員會(SEC)提交了明確的補充材料。這些材料與1934年《證券交易法》附表14A下的委託書有關。DEFA14A 表格所示,該申請是一項修正案,包括更多材料,但不需要額外的申請費。該文件由EyePoint Pharmicals作爲註冊人提交,不涉及任何第三方申報人。公告中沒有具體說明額外材料的性質。
EyePoint Pharmicals, Inc.已於2024年4月26日向美國證券交易委員會(SEC)提交了明確的補充材料。這些材料與1934年《證券交易法》附表14A下的委託書有關。DEFA14A 表格所示,該申請是一項修正案,包括更多材料,但不需要額外的申請費。該文件由EyePoint Pharmicals作爲註冊人提交,不涉及任何第三方申報人。公告中沒有具體說明額外材料的性質。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息